BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 19620247)

  • 21. Thrombopoietin (TPO) induces c-myc expression through a PI3K- and MAPK-dependent pathway that is not mediated by Akt, PKCzeta or mTOR in TPO-dependent cell lines and primary megakaryocytes.
    Chanprasert S; Geddis AE; Barroga C; Fox NE; Kaushansky K
    Cell Signal; 2006 Aug; 18(8):1212-8. PubMed ID: 16380230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin is necessary for hypoxia-induced pulmonary artery adventitial fibroblast proliferation.
    Gerasimovskaya EV; Tucker DA; Stenmark KR
    J Appl Physiol (1985); 2005 Feb; 98(2):722-31. PubMed ID: 15501927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
    Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
    Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
    Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
    Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.
    Zatelli MC; Minoia M; Martini C; Tagliati F; Ambrosio MR; Schiavon M; Buratto M; Calabrese F; Gentilin E; Cavallesco G; Berdondini L; Rea F; degli Uberti EC
    Endocr Relat Cancer; 2010 Sep; 17(3):719-29. PubMed ID: 20554786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TOR kinase and Ran are downstream from PI3K/Akt in H2O2-induced mitosis.
    Radisavljevic ZM; González-Flecha B
    J Cell Biochem; 2004 Apr; 91(6):1293-300. PubMed ID: 15048882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositide-3-OH kinase (PI3K)/Akt pathways regulate activation of E-twenty-six (ETS)-like transcription factor 1 (Elk-1) in U138 glioblastoma cells.
    Mut M; Lule S; Demir O; Kurnaz IA; Vural I
    Int J Biochem Cell Biol; 2012 Feb; 44(2):302-10. PubMed ID: 22085529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
    Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
    Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process.
    Yu C; Rahmani M; Almenara J; Sausville EA; Dent P; Grant S
    Oncogene; 2004 Feb; 23(7):1364-76. PubMed ID: 14647418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ames dwarf (Prop1(df)/Prop1(df)) mice display increased sensitivity of the major GH-signaling pathways in liver and skeletal muscle.
    Miquet JG; Muñoz MC; Giani JF; González L; Dominici FP; Bartke A; Turyn D; Sotelo AI
    Growth Horm IGF Res; 2010 Apr; 20(2):118-26. PubMed ID: 20022531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma.
    Feng W; Brown RE; Trung CD; Li W; Wang L; Khoury T; Alrawi S; Yao J; Xia K; Tan D
    Ann Clin Lab Sci; 2008; 38(3):195-209. PubMed ID: 18715846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression.
    Kang MH; Oh SC; Lee HJ; Kang HN; Kim JL; Kim JS; Yoo YA
    Exp Cell Res; 2011 Jul; 317(12):1746-62. PubMed ID: 21570392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
    McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Montalto G; Cervello M; Nicoletti F; Fagone P; Malaponte G; Mazzarino MC; Candido S; Libra M; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Milella M; Tafuri A; Cocco L; Evangelisti C; Chiarini F; Martelli AM
    Oncotarget; 2012 Sep; 3(9):954-87. PubMed ID: 23006971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization and functional activity of thrombin receptors in the human lens.
    James C; Collison DJ; Duncan G
    Invest Ophthalmol Vis Sci; 2005 Mar; 46(3):925-32. PubMed ID: 15728549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crosstalk between PI3 kinase/PDK1/Akt/Rac1 and Ras/Raf/MEK/ERK pathways downstream PDGF receptor.
    Niba ET; Nagaya H; Kanno T; Tsuchiya A; Gotoh A; Tabata C; Kuribayashi K; Nakano T; Nishizaki T
    Cell Physiol Biochem; 2013; 31(6):905-13. PubMed ID: 23817184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
    Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
    Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT.
    Mirza AM; Gysin S; Malek N; Nakayama K; Roberts JM; McMahon M
    Mol Cell Biol; 2004 Dec; 24(24):10868-81. PubMed ID: 15572689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
    Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
    J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PI3K/Akt and mTOR/p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress-induced apoptosis.
    Faghiri Z; Bazan NG
    Exp Eye Res; 2010 Jun; 90(6):718-25. PubMed ID: 20230819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.